DONNA-MARIE KOROMA

Allopathic & Osteopathic Physicians|Family Medicine SPARTANBURG, SC NPI 1457366262

General Payments — all program years on this page

$3,046.30

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 137
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $307.01 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $307.0119

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Novo Nordisk AS $68.625
Amgen Inc. $61.733
GlaxoSmithKline, LLC. $42.453
Lilly USA, LLC $29.862
NOVARTIS PHARMACEUTICALS CORPORATION $20.001
Astellas Pharma US Inc $18.891
Exact Sciences Corporation $18.601
DEXCOM, INC. $16.961
ITI, Inc. $16.261
ABBVIE INC. $13.641

By program year

Program yearAmountRecords
2018 $1,253.5541
2019 $861.1639
2020 $184.1213
2023 $440.4625
2024 $307.0119

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087039836 Novartis Pharmaceuticals Corporation $20.00 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096769512 Novo Nordisk Inc $13.08 06/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096950556 Novo Nordisk Inc $13.08 08/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097093886 Novo Nordisk Inc $13.60 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097239514 Novo Nordisk Inc $13.08 05/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097769116 Novo Nordisk Inc $15.78 09/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104100224 ABBVIE INC. $13.64 02/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111623262 Amgen Inc. $29.60 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114740550 Exact Sciences Corporation $18.60 08/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116136953 GlaxoSmithKline, LLC. $14.94 06/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116372101 GlaxoSmithKline, LLC. $14.06 10/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116481225 GlaxoSmithKline, LLC. $13.45 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117300783 Amgen Inc. $16.12 05/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117300785 Amgen Inc. $16.01 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136149648 Lilly USA, LLC $14.42 04/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136160817 Lilly USA, LLC $15.44 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139385522 Astellas Pharma US Inc $18.89 09/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143259134 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $16.26 10/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153296986 Dexcom, Inc. $16.96 02/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.